Cargando…

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

BACKGROUND: The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphocytic leukemia (ALL). This study was to identify serum candidate peptides for monitoring MRD in adult ALL. RESULTS: A total of 33 peptides in the molecular weight ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Ju, He, Aili, Huang, Chen, Yang, Juan, Zhang, Wanggang, Wang, Jianli, Yang, Yun, Zhang, Pengyu, Zhang, Yang, Zhou, Fuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195909/
https://www.ncbi.nlm.nih.gov/pubmed/25317080
http://dx.doi.org/10.1186/s12953-014-0049-y
_version_ 1782339382011756544
author Bai, Ju
He, Aili
Huang, Chen
Yang, Juan
Zhang, Wanggang
Wang, Jianli
Yang, Yun
Zhang, Pengyu
Zhang, Yang
Zhou, Fuling
author_facet Bai, Ju
He, Aili
Huang, Chen
Yang, Juan
Zhang, Wanggang
Wang, Jianli
Yang, Yun
Zhang, Pengyu
Zhang, Yang
Zhou, Fuling
author_sort Bai, Ju
collection PubMed
description BACKGROUND: The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphocytic leukemia (ALL). This study was to identify serum candidate peptides for monitoring MRD in adult ALL. RESULTS: A total of 33 peptides in the molecular weight range of 1000-10000 Da were detected using ClinProt system and statistically different between adult patients with ALL and healthy controls. Quick classifier (QC) algorithm was used to obtain a diagnostic model consisting of five peptides that could discriminate patients with ALL from controls with a high sensitivity (100%) and specificity (96.67%). The peptides in the QC model were identified as fibrinogen alpha chain (FGA), glutathione S-transferase P1 (GSTP1), isoform 1 of fibrinogen alpha chain precursor, platelet factor 4 (PF4) by high pressure/performance liquid chromatography mass spectrometry/mass spectrometry. Relative intensities of the five peptides were compared among ALL different groups for the potential importance of MRD evaluation in ALL. The peptides with increased relative intensities in newly diagnosed (ND) ALL patients were found to be decreased in their relative intensities after complete remission (CR) of adult ALL. When ALL patients were refractory & relapsed (RR), relative intensities of the peptides were elevated again. Peptides with decreased relative intensities in ND and RR ALL patients were found to be increased in their relative intensities when ALL patients achieved CR. The findings were validated by ELISA and western blot. Further linear regression analyses were performed to eliminate the influence of platelet and white blood cell counts on serum protein contents and indicated that there were no correlations between the contents of all four proteins (PF4, connective tissue active peptide III, FGA and GSTP1) and white blood cell or platelet counts in ALL different groups and healthy control. CONCLUSIONS: We speculate the five peptides, FGA, isoform 1 of fibrinogen alpha chain precursor, GSTP1, PF4 and connective tissue active peptide III would be potential biomarkers for forecasting relapse, monitoring MRD and evaluating therapeutic response in adult ALL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12953-014-0049-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4195909
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41959092014-10-15 Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia Bai, Ju He, Aili Huang, Chen Yang, Juan Zhang, Wanggang Wang, Jianli Yang, Yun Zhang, Pengyu Zhang, Yang Zhou, Fuling Proteome Sci Research Article BACKGROUND: The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphocytic leukemia (ALL). This study was to identify serum candidate peptides for monitoring MRD in adult ALL. RESULTS: A total of 33 peptides in the molecular weight range of 1000-10000 Da were detected using ClinProt system and statistically different between adult patients with ALL and healthy controls. Quick classifier (QC) algorithm was used to obtain a diagnostic model consisting of five peptides that could discriminate patients with ALL from controls with a high sensitivity (100%) and specificity (96.67%). The peptides in the QC model were identified as fibrinogen alpha chain (FGA), glutathione S-transferase P1 (GSTP1), isoform 1 of fibrinogen alpha chain precursor, platelet factor 4 (PF4) by high pressure/performance liquid chromatography mass spectrometry/mass spectrometry. Relative intensities of the five peptides were compared among ALL different groups for the potential importance of MRD evaluation in ALL. The peptides with increased relative intensities in newly diagnosed (ND) ALL patients were found to be decreased in their relative intensities after complete remission (CR) of adult ALL. When ALL patients were refractory & relapsed (RR), relative intensities of the peptides were elevated again. Peptides with decreased relative intensities in ND and RR ALL patients were found to be increased in their relative intensities when ALL patients achieved CR. The findings were validated by ELISA and western blot. Further linear regression analyses were performed to eliminate the influence of platelet and white blood cell counts on serum protein contents and indicated that there were no correlations between the contents of all four proteins (PF4, connective tissue active peptide III, FGA and GSTP1) and white blood cell or platelet counts in ALL different groups and healthy control. CONCLUSIONS: We speculate the five peptides, FGA, isoform 1 of fibrinogen alpha chain precursor, GSTP1, PF4 and connective tissue active peptide III would be potential biomarkers for forecasting relapse, monitoring MRD and evaluating therapeutic response in adult ALL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12953-014-0049-y) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-16 /pmc/articles/PMC4195909/ /pubmed/25317080 http://dx.doi.org/10.1186/s12953-014-0049-y Text en © Bai et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bai, Ju
He, Aili
Huang, Chen
Yang, Juan
Zhang, Wanggang
Wang, Jianli
Yang, Yun
Zhang, Pengyu
Zhang, Yang
Zhou, Fuling
Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title_full Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title_fullStr Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title_full_unstemmed Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title_short Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
title_sort serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195909/
https://www.ncbi.nlm.nih.gov/pubmed/25317080
http://dx.doi.org/10.1186/s12953-014-0049-y
work_keys_str_mv AT baiju serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT heaili serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT huangchen serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT yangjuan serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT zhangwanggang serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT wangjianli serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT yangyun serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT zhangpengyu serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT zhangyang serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia
AT zhoufuling serumpeptidomebasedbiomarkerssearchingformonitoringminimalresidualdiseaseinadultacutelymphocyticleukemia